Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Boston Scientific discloses cybersecurity incident causing global disruption
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Momenta Phama (MNTA) Misses Q2 EPS by 77c, Revenues Miss
August 2, 2019 7:07 AM EDTMomenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($1.19), $0.77 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $9.2 million.
At Momenta, we are focused on leveraging our teams expertise in the engineering of biologics and our deep... More
